Robert J. Mullin

4.1k total citations · 3 hit papers
37 papers, 3.0k citations indexed

About

Robert J. Mullin is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Robert J. Mullin has authored 37 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 18 papers in Molecular Biology and 7 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Robert J. Mullin's work include HER2/EGFR in Cancer Research (8 papers), Biochemical and Molecular Research (7 papers) and Monoclonal and Polyclonal Antibodies Research (7 papers). Robert J. Mullin is often cited by papers focused on HER2/EGFR in Cancer Research (8 papers), Biochemical and Molecular Research (7 papers) and Monoclonal and Polyclonal Antibodies Research (7 papers). Robert J. Mullin collaborates with scholars based in United States, Netherlands and United Kingdom. Robert J. Mullin's co-authors include David W. Rusnak, Barry R. Keith, Tona M. Gilmer, Krystal J. Alligood, Glenn Spehar, Hong Ma, Edgar R. Wood, Gary Owens, Neil L. Spector and Wenle Xia and has published in prestigious journals such as Journal of Biological Chemistry, Cancer and Cancer Research.

In The Last Decade

Robert J. Mullin

36 papers receiving 2.9k citations

Hit Papers

Activity of the Dual Kinase Inhibitor Lapatinib (GW572016... 2001 2026 2009 2017 2006 2001 2002 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Activity of the Dual Kinase Inhibitor Lapatinib (GW572016) against HER-2-Overexpressing and Trastuzumab-Treated Breast Cancer Cells
    2006 711 citations Gottfried E. Konecny, Mark D. Pegram et al. Cancer Research profile →
  2. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.
    2001 590 citations David W. Rusnak, Karen Lackey et al. PubMed profile →
  3. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways
    2002 548 citations Wenle Xia, Robert J. Mullin et al. Oncogene profile →

Peers

Robert J. Mullin
Charles Zacharchuk United States
Krystal J. Alligood United States
Wenle Xia United States
Ralf Brandt United States
Anne T. Truesdale United States
Paul Kussie United States
Neil L. Spector United States
Helmout Modjtahedi United Kingdom
Anke Baum Austria
Terence O’Reilly Switzerland
Charles Zacharchuk United States
Robert J. Mullin
Citations per year, relative to Robert J. Mullin Robert J. Mullin (= 1×) peers Charles Zacharchuk

Countries citing papers authored by Robert J. Mullin

Since Specialization
Citations

This map shows the geographic impact of Robert J. Mullin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert J. Mullin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert J. Mullin more than expected).

Fields of papers citing papers by Robert J. Mullin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert J. Mullin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert J. Mullin. The network helps show where Robert J. Mullin may publish in the future.

Co-authorship network of co-authors of Robert J. Mullin

This figure shows the co-authorship network connecting the top 25 collaborators of Robert J. Mullin. A scholar is included among the top collaborators of Robert J. Mullin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert J. Mullin. Robert J. Mullin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Prins, Robert M., et al.. (2016). Combination immune checkpoint inhibitors for the treatment of human colon carcinoma in NSG mice engrafted with human PBMC. European Journal of Cancer. 69. S58–S58. 1 indexed citations
2.
Hall, Jason C., Laura A. Marlow, William F. Durham, et al.. (2016). Novel patient-derived xenograft mouse model for pancreatic acinar cell carcinoma demonstrates single agent activity of oxaliplatin. Journal of Translational Medicine. 14(1). 129–129. 13 indexed citations
3.
Molina, Julian R., Scott H. Kaufmann, Joel M. Reid, et al.. (2008). Evaluation of Lapatinib and Topotecan Combination Therapy: Tissue Culture, Murine Xenograft, and Phase I Clinical Trial Data. Clinical Cancer Research. 14(23). 7900–7908. 41 indexed citations
4.
Rheault, Tara, Thomas R. Caferro, Scott H. Dickerson, et al.. (2008). Thienopyrimidine-based dual EGFR/ErbB-2 inhibitors. Bioorganic & Medicinal Chemistry Letters. 19(3). 817–820. 72 indexed citations
5.
Kumar, Rakesh, Victoria B. Knick, Sharon K. Rudolph, et al.. (2007). Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Molecular Cancer Therapeutics. 6(7). 2012–2021. 423 indexed citations
6.
7.
Konecny, Gottfried E., Mark D. Pegram, Natarajan Venkatesan, et al.. (2006). Activity of the Dual Kinase Inhibitor Lapatinib (GW572016) against HER-2-Overexpressing and Trastuzumab-Treated Breast Cancer Cells. Cancer Research. 66(3). 1630–1639. 711 indexed citations breakdown →
8.
Dev, I K, Ronna E. Dornsife, Teresa M. Hopper, et al.. (2004). Antitumour efficacy of VEGFR2 tyrosine kinase inhibitor correlates with expression of VEGF and its receptor VEGFR2 in tumour models. British Journal of Cancer. 91(7). 1391–1398. 35 indexed citations
9.
Gaul, Micheal D., Yu Guo, Karen Affleck, et al.. (2003). Discovery and Biological Evaluation of Potent Dual ErbB-2/EGFR Tyrosine Kinase Inhibitors: 6-Thiazolylquinazolines. Bioorganic & Medicinal Chemistry Letters. 13(4). 637–640. 40 indexed citations
10.
Xia, Wenle, Robert J. Mullin, Barry R. Keith, et al.. (2002). Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene. 21(41). 6255–6263. 548 indexed citations breakdown →
11.
12.
Smith, Gary K., Todd A. Blumenkopf, Michael Cory, et al.. (1997). Toward Antibody-directed Enzyme Prodrug Therapy with the T268G Mutant of Human Carboxypeptidase A1 and Novel in VivoStable Prodrugs of Methotrexate. Journal of Biological Chemistry. 272(25). 15804–15816. 42 indexed citations
13.
Jansen, Marilyn, Michael Dykstra, Jeremy N. Stables, et al.. (1994). Effect of purine synthesis inhibition on WiDr spheroids in vitro or on WiDr or colon 38 tumors in vivo. Biochemical Pharmacology. 47(6). 1067–1078. 7 indexed citations
14.
Priest, David G., Marlene A. Bunni, Robert J. Mullin, et al.. (1992). A Comparison of Hplc and Ternary Complex-Based Assays of Tissue Reduced Folates. Analytical Letters. 25(2). 219–230. 5 indexed citations
15.
Mullin, Robert J. & David S. Duch. (1991). Preparation of a chiral matrix. Journal of Chromatography A. 555(1-2). 254–259. 3 indexed citations
16.
Comley, John C.W., et al.. (1991). Microculture screening assay for primary in vitro evaluation of drugs against Pneumocystis carinii. Antimicrobial Agents and Chemotherapy. 35(10). 1965–1974. 25 indexed citations
17.
Smith, Gary K., Thomas J. Monaco, R. Rigual, et al.. (1990). Activity of an NAD-dependent 5,10-methylenetetrahydrofolate dehydrogenase in normal tissue, neoplastic cells, and oncogene-transformed cells. Archives of Biochemistry and Biophysics. 283(2). 367–371. 23 indexed citations
18.
Johnson, Dana L., Robert J. Mullin, David S. Duch, & Stephen J. Benkovic. (1990). Direct demonstration of the active salvage of preformed purines by murine tumors. Biochemical and Biophysical Research Communications. 170(3). 1164–1169. 1 indexed citations
19.
Laufman, Leslie R., Wayne D. Brenckman, Mary Collier, et al.. (1989). Clinical experience with leucovorin and 5-fluorouracil. Cancer. 63(S6). 1031–1035. 23 indexed citations
20.
Laufman, Leslie R., Wayne D. Brenckman, Mary Collier, et al.. (1988). Clinical Experience with CF-FUra. Advances in experimental medicine and biology. 244. 201–211. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Charles Zacharchuk Breakdown of academic impact, for papers by Krystal J. Alligood Breakdown of academic impact, for papers by Wenle Xia Breakdown of academic impact, for papers by Ralf Brandt Breakdown of academic impact, for papers by Anne T. Truesdale Breakdown of academic impact, for papers by Paul Kussie Breakdown of academic impact, for papers by Neil L. Spector Breakdown of academic impact, for papers by Helmout Modjtahedi Breakdown of academic impact, for papers by Anke Baum Breakdown of academic impact, for papers by Terence O’Reilly
Rankless by CCL
2026